3 results
Approved WMOCompleted
The study will look at patients with relapsed (returned after prior treatment) and refractory (not responsive to prior treatment) multiple myeloma. The research aims to compare a new drug called elotuzamab combined with standard of care (…
Approved WMOCompleted
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
Approved WMORecruiting
To investigate whether mifepristone (7-day, 1200 mg/day) added to treatment as usual (TAU), is more efficacious than placebo in reducing depressive symptom severity (Inventory of Depressive Symptoms-Self Rated questionnaire; IDS-SR) in patients with…